Filtered By:
Specialty: Infectious Diseases

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 742 results found since Jan 2013.

Maternal Immunization: Opportunities for Scientific Advancement
Maternal immunization is an effective strategy to prevent and/or minimize the severity of infectious diseases in pregnant women and their infants. Based on the success of vaccination programs to prevent maternal and neonatal tetanus, maternal immunization has been well received in the United States and globally as a promising strategy for the prevention of other vaccine-preventable diseases that threaten pregnant women and infants, such as influenza and pertussis. Given the promise for reducing the burden of infectious conditions of perinatal significance through the development of vaccines against relevant pathogens, the ...
Source: Clinical Infectious Diseases - November 25, 2014 Category: Infectious Diseases Authors: Beigi, R. H., Fortner, K. B., Munoz, F. M., Roberts, J., Gordon, J. L., Han, H. H., Glenn, G., Dormitzer, P. R., Gu, X. X., Read, J. S., Edwards, K., Patel, S. M., Swamy, G. K. Tags: INCLUDING PREGNANT WOMEN IN CLINICAL TRIALS OF ANTIMICROBIALS AND VACCINES Source Type: research

Assessment of Safety in Newborns of Mothers Participating in Clinical Trials of Vaccines Administered During Pregnancy
A panel of experts convened by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, developed proposed guidelines for the evaluation of adverse events in newborns of women participating in clinical trials of maternal immunization in the United States.
Source: Clinical Infectious Diseases - November 25, 2014 Category: Infectious Diseases Authors: Munoz, F. M., Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., Nesin, M. Tags: INCLUDING PREGNANT WOMEN IN CLINICAL TRIALS OF ANTIMICROBIALS AND VACCINES Source Type: research

Assessment of Congenital Anomalies in Infants Born to Pregnant Women Enrolled in Clinical Trials
In 2011 and 2012, the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, held a series of meetings to provide guidance to investigators regarding study design of clinical trials of vaccines and antimicrobial medications that enroll pregnant women. Assessment of congenital anomalies among infants born to women enrolled in these trials was recognized as a challenging issue, and a workgroup with expertise in epidemiology, pediatrics, genetics, dysmorphology, clinical trials, and infectious diseases was formed to address this issue. The ...
Source: Clinical Infectious Diseases - November 25, 2014 Category: Infectious Diseases Authors: Rasmussen, S. A., Hernandez-Diaz, S., Abdul-Rahman, O. A., Sahin, L., Petrie, C. R., Keppler-Noreuil, K. M., Frey, S. E., Mason, R. M., Nesin, M., Carey, J. C. Tags: INCLUDING PREGNANT WOMEN IN CLINICAL TRIALS OF ANTIMICROBIALS AND VACCINES Source Type: research

Designing Drug Trials: Considerations for Pregnant Women
Clinical pharmacology studies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical for informing on the safe and effective use of drugs during pregnancy. That being said, multiple factors have hindered the ability to study drugs in pregnant patients. These include concerns for maternal and fetal safety, ethical considerations, the difficulty in designing appropriate trials to assess the study objectives, and funding limitations. This document summarizes the recommendations of a panel of experts convened by the Division of Microbiology and Infectious Diseases at the National Instit...
Source: Clinical Infectious Diseases - November 25, 2014 Category: Infectious Diseases Authors: Sheffield, J. S., Siegel, D., Mirochnick, M., Heine, R. P., Nguyen, C., Bergman, K. L., Savic, R. M., Long, J., Dooley, K. E., Nesin, M. Tags: INCLUDING PREGNANT WOMEN IN CLINICAL TRIALS OF ANTIMICROBIALS AND VACCINES Source Type: research

Scientists report on trial of early-generation Ebola, Marburg vaccine candidates
(NIH/National Institute of Allergy and Infectious Diseases) esults of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses -- the first to be completed in an African country -- showed that they were safe and induced immune responses in healthy Ugandan adult volunteers.
Source: EurekAlert! - Infectious and Emerging Diseases - December 23, 2014 Category: Infectious Diseases Source Type: news

Progress Toward Curing HIV Infections With Hematopoietic Stem Cell Transplantation
Combination antiretroviral therapy can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate the virus. A major obstacle in the quest for a cure is the difficulty in targeting and measuring latently infected cells. To date, a single person seems to have been cured of HIV. Hematopoietic stem cell transplantation (HSCT) preceded this cancer patient's long-term sustained HIV remission, but researchers have been unable to replicate this cure, and the mechanisms that led to HIV remission remain to be established. In February 2014, the National Institute of Allergy and Infectious Diseases sponsore...
Source: Clinical Infectious Diseases - December 23, 2014 Category: Infectious Diseases Authors: Smiley, S. T., Singh, A., Read, S. W., Sharma, O. K., Finzi, D., Lane, C., Rice, J. S. Tags: HIV/AIDS Source Type: research

NIH grantees overcome hurdle to kill HIV-infected cells brought out of hiding
(NIH/National Institute of Allergy and Infectious Diseases) A major obstacle to curing people of HIV infection is the way the virus hides, in a reservoir primarily of dormant immune cells called resting memory CD4+ T cells. One potential approach to curing HIV infection is to awaken these latent CD4+ T cells so they start making HIV proteins. This would alert the immune system that the cells are infected, and, in theory, generate an immune response that kills them.
Source: EurekAlert! - Infectious and Emerging Diseases - January 7, 2015 Category: Infectious Diseases Source Type: news

High hepatitis C cure rate seen in NIH-led trial of 6-week oral drug regimens
(NIH/National Institute of Allergy and Infectious Diseases) Thirty-eight of 40 volunteers with hepatitis C virus (HCV) infections who received a combination of three direct-acting oral drugs for six weeks were cured in a clinical trial conducted at the National Institutes of Health. A six-week course of therapy is half the length of time previously shown to achieve a similar cure rate using two direct-acting oral HCV drugs only. The trial findings appear in The Lancet.
Source: EurekAlert! - Infectious and Emerging Diseases - January 12, 2015 Category: Infectious Diseases Source Type: news

TLR9: Two rings to bind them?
(University of Tokyo) University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Source: EurekAlert! - Infectious and Emerging Diseases - February 9, 2015 Category: Infectious Diseases Source Type: news

NIH Ebola study in macaques provides timeframes for post-mortem viral stability
(NIH/National Institute of Allergy and Infectious Diseases) To determine how long Ebola virus could remain infectious in a body after death, NIH scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem.
Source: EurekAlert! - Infectious and Emerging Diseases - February 12, 2015 Category: Infectious Diseases Source Type: news

Allergic Reactions After Egg-Free Recombinant Influenza Vaccine: Reports to the US Vaccine Adverse Event Reporting System
The Vaccine Adverse Event Reporting System has received reports of allergic reactions following immunization with egg-free recombinant influenza vaccine, among patients with a self-reported egg allergy or previous allergic reaction to inactivated influenza vaccine. These results suggest that allergic reactions following influenza vaccination are not necessarily related to egg proteins.
Source: Clinical Infectious Diseases - February 16, 2015 Category: Infectious Diseases Authors: Woo, E. J. Tags: BRIEF REPORTS Source Type: research

Experimental Ebola vaccine safe, prompts immune response
(NIH/National Institute of Allergy and Infectious Diseases) An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health and the Walter Reed Army Institute of Research found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it.
Source: EurekAlert! - Infectious and Emerging Diseases - April 1, 2015 Category: Infectious Diseases Source Type: news

VSV-EBOV Ebola vaccine appears safe and generates immune response
(US Army Medical Research Institute of Infectious Diseases) An experimental Ebola vaccine called VSV-EBOV appears safe and elicited a robust immune response in a small phase 1 clinical trial, according to findings to be published in the New England Journal of Medicine on April 2, 2015. Two independent but coordinated studies, performed at the Walter Reed Army Institute of Research and the National Institute of Allergy and Infectious Diseases, explored the safety and immunogenicity of the investigational vaccine when administered at different dosages.
Source: EurekAlert! - Infectious and Emerging Diseases - April 1, 2015 Category: Infectious Diseases Source Type: news

NIH, South African Medical Research Council award $8 million in HIV, TB grants
(NIH/National Institute of Allergy and Infectious Diseases) NIH and the South African Medical Research Council are awarding 31 grants to US and South African scientists to support research targeting HIV/AIDS, tuberculosis and HIV-related co-morbidities and cancers. The awards, which total $8 million in first-year funding, are the first to be issued through the South Africa-US Program for Collaborative Biomedical Research.
Source: EurekAlert! - Infectious and Emerging Diseases - April 13, 2015 Category: Infectious Diseases Source Type: news

High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia
Conclusion Cephalosporins and fluoroquinolones use in pneumonia is highly variable among EDs. The majority of these prescriptions are avoidable. Antibiotic stewardship programs should be implemented to restrict their use in EDs.
Source: Infection - May 22, 2015 Category: Infectious Diseases Source Type: research